IKKepsilon/TBK1 Inhibitors for the Treatment of Obesity and Type 2 Diabetes

IKKepsilon/TBK1 抑制剂用于治疗肥胖和 2 型糖尿病

• 批准号: 8610448
• 负责人: ALAN R. SALTIEL
• 金额: $ 59.49万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8610448
• 关键词: Adipocytes; Adipose tissue; Allergic rhinitis; Asthma; Attenuated; Biological Markers; Body Weight decreased; Cataloging; Catalogs; Cells; Characteristics; Chemicals; Chronic; Clinic; Clinical; Data; Development; Diabetes Mellitus; Diet; Disease; Drug Kinetics; Effectiveness; Energy Metabolism; Ensure; Enzymes; Epidemic; Fatty Liver; Fatty acid glycerol esters; Feedback; Gene Expression; Generations; Genes; Goals; Half-Life; Hepatocyte; Human; IKKepsilon; In Vitro; Inflammation; Inflammatory; Insulin; Insulin Resistance; Intellectual Property; Knock-out; Laboratories; Link; Liver; Liver diseases; Mediating; Metabolic; Metabolism; Modality; Modeling; Monitor; Mus; Non-Insulin-Dependent Diabetes Mellitus; Obese Mice; Obesity; Overnutrition; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Phosphotransferases; Play; Positioning Attribute; Property; Protein Kinase; Proteins; Resolution; Rodent Model; Role; Solubility; Specificity; Sterile coverings; Structure; TBK1 gene; Tars; Thermogenesis; Uncertainty; Weight; Work; X-Ray Crystallography; amlexanox; analog; aqueous; base; design; experience; feeding; functional group; improved; in vivo; inhibitor/antagonist; insight; insulin sensitivity; interest; kinase inhibitor; mouse model; non-alcoholic fatty liver; novel; novel strategies; novel therapeutics; obesity treatment; patient population; prevent; programs; public health relevance; response; trait

DESCRIPTION (provided by applicant): There is little doubt that we are in the midst of a worldwide epidemic of diabetes. Insulin resistance is recognized as a characteristic trait of the disease, defined by the inability to respond to normal circulating levels of insulin, and is usuall closely associated with obesity. Recent data suggest an inflammatory link between obesity and insulin resistance. We hypothesize that the induction of a counter-inflammatory program downstream of NF?B plays a key role in preserving energy storage, reducing energy expenditure and ensuring that insulin resistance is maintained during obesity. To this end, we have searched for inhibitors of the noncanonical IKK's TBK1 and IKK¿, and plan to develop these as new therapeutic modalities. We will pursue this plan with three aims: 1) We will development analogs of the newly discovered inhibitor amlexanox with increased potency and metabolic stability, using both medicinal chemistry and structure- based design approaches; 2) We will develop novel inhibitors of IKK¿ and TBK1 that represent new chemical entities, driven by increased potency, improved pharmaceutical properties and in vivo activity in mouse models of obese type 2 diabetes; and 3) In order to support the clinical development of these new compounds, we will develop in vivo biomarkers for IKK¿/TBK1 inhibition.

描述（由申请人提供）：毫无疑问，我们正处于糖尿病的全球流行之中。胰岛素抵抗被认为是糖尿病的一个特征，其定义为不能对正常循环水平的胰岛素作出反应，并且通常与肥胖密切相关。最近的数据表明肥胖和胰岛素抵抗之间存在炎症联系。我们假设，诱导的抗炎程序下游的NF？B在保持能量储存、减少能量消耗和确保肥胖期间维持胰岛素抵抗方面起着关键作用。为此，我们寻找了非经典IKK的TBK 1和IKK <$的抑制剂，并计划将其作为新的治疗方式。我们将通过三个目标来实现这一计划：1）我们将开发新发现的抑制剂氨来诺的类似物，其效力和代谢稳定性增加，使用药物化学和基于结构的设计方法; 2）我们将开发新型IKK抑制剂。和TBK 1代表新的化学实体，由增加的效力驱动，改善的药物特性和在肥胖2型糖尿病小鼠模型中的体内活性;和3）为了支持这些新化合物的临床开发，我们将开发用于IKK 1/TBK 1抑制的体内生物标志物。